Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type

RS Mehta, D Marin, A Alousi, CG Kanakry… - Blood …, 2023 - ashpublications.org
Haploidentical hematopoietic cell transplantation (HCT) with posttransplant
cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis yields a similar …

[HTML][HTML] Impact of donor age in haploidentical-post-transplantation cyclophosphamide versus matched unrelated donor post-transplantation cyclophosphamide …

RS Mehta, J Ramdial, D Marin, A Alousi… - … and Cellular Therapy, 2023 - Elsevier
Haploidentical hematopoietic cell transplantation (HCT) with post-transplantation
cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis is associated with …

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation

MM Al Malki, D Yang, M Labopin, B Afanasyev… - Blood …, 2020 - ashpublications.org
We compared outcomes of 1461 adult patients with acute lymphoblastic leukemia (ALL)
receiving hematopoietic cell transplantation (HCT) from a haploidentical (n= 487) or …

[HTML][HTML] Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute …

J Sanz, JE Galimard, M Labopin, B Afanasyev… - Journal of Hematology & …, 2021 - Springer
Background There is no information on the impact of donor type in allogeneic hematopoietic
stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis …

Posttransplant cyclophosphamide‐based anti–graft‐vs‐host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with …

A Nagler, M Labopin, M Arat, P Reményi, Y Koc… - Cancer, 2022 - Wiley Online Library
Background Both mismatched unrelated donor (MMUD) and haploidentical (haplo)
transplantation are valid options in patients with high‐risk acute lymphoblastic leukemia …

[HTML][HTML] Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a …

A Nagler, M Labopin, M Houhou, M Aljurf… - Journal of Hematology & …, 2021 - Springer
Background Non-T-cell depleted haploidentical hematopoietic stem cell transplantation
(HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with …

Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for …

AH Bazarbachi, M Labopin, AM Raiola, D Blaise… - Cancer, 2024 - Wiley Online Library
Background The optimal choice for graft‐versus‐host disease (GVHD) prophylaxis in
haploidentical stem cell transplantation (haplo‐SCT) remains debatable. Posttransplant …

Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute …

F Lorentino, M Labopin, F Ciceri, L Vago… - Leukemia, 2021 - nature.com
HLA-matching largely contributes to unrelated donor hematopoietic cell transplantation (UD-
HCT) success but, due to the selective deletion of alloreactive T-cells, post-transplantation …

[HTML][HTML] Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute …

A Nagler, AS Kanate, M Labopin, F Ciceri… - …, 2021 - ncbi.nlm.nih.gov
Graft-versus-host disease (GvHD) prophylaxis for unmanipulated haploidentical
hematopoietic cell transplantation includes posttransplant cyclophosphamide (PTCy) and …

The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis

F Lorentino, M Labopin, K Fleischhauer… - Blood …, 2017 - ashpublications.org
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with unmanipulated
grafts is increasingly adopted for high-risk acute leukemia, with acute graft-versus-host …